|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4225 USD | 0.00% |
|
+0.36% | -13.26% |
| 06-18 | Akili's EndeavorOTC Gets FDA Clearance For ADHD Treatment | MT |
| 06-18 | Akili Gets FDA Clearance for ADHD Video Game Over-the-Counter Treatment | DJ |
Akili, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 0.383 million compared to USD 0.113 million a year ago. Net loss was USD 9.76 million compared to USD 20.71 million a year ago.
Basic loss per share from continuing operations was USD 0.12 compared to USD 0.27 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -13.26% | 33.49M | |
| +7.23% | 217B | |
| +11.31% | 191B | |
| +28.94% | 154B | |
| +32.00% | 112B | |
| +0.11% | 62.75B | |
| +16.09% | 53.34B | |
| +0.94% | 48.88B | |
| -2.97% | 39.36B | |
| +1.23% | 35.73B |
AKILI, INC. 
